Naomi Balaban from Dudley, MA, age 67

President

view source

Location:

185 Wet Main St, Hopkinton, MA

Industry:

Biotechnology

Work:

Yale University Apr 2010 - Aug 2011
Associate
Staphoff Biotech Apr 2010 - Aug 2011
President
Centegen Dec 2005 - Jan 2011
Director
Tufts University Nov 2002 - Apr 2010
Assistant Professor

Education:

Weizmann Institute of Science 1984 - 1990
Doctorates, Doctor of Philosophy, Biology

Skills:

Biotechnology
Molecular Biology
Biochemistry
Lifesciences
Science
Cell Culture
Research
Genetics
Cell Biology
Drug Discovery
Teaching
Genomics
Immunology
Microbiology
Pcr
Statistics
Western Blotting
Data Analysis
Surgery

Owner

view source

Location:

1601 Barton Rd, Redlands, CA 92373

Industry:

Biotechnology

Work:

Tufts University
Faculty, Tufts University
Centegen
Owner

Education:

Weizmann Institute of Science 1984 - 1990

Founder

view source

Location:

Hopkinton, MA

Industry:

Biotechnology

Work:

Staphoff Biotech
Founder

Naomi Balaban Hopkinton, MA

view source

Work:

StaphOff Biotech Inc

2011 to 2000
Founder Centegen Inc

2005 to 2000
Co-founder Centegen Inc
New Haven, CT
2010 to 2011
Lab Associate, Department of Chemical Engineering Tufts University Cummings School of Veterinary Medicine
North Grafton, MA
2002 to 2010
Assistant Professor Sackler School of Medicine
-,
1999 to 2005
Lecturer, Human Microbiology Department University of California Davis
Davis, CA
1997 to 2001
Adjunct Assistant Professor Department of Internal Medicine, Primate Research Center
Davis, CA
1995 to 1996
Postdoctoral Fellow Department of Molecular Pathogenesis
New York, NY
1992 to 1994
Postdoctoral Fellow

Education:

Weizmann Inst of Science
1985 to 1990
PhD in Research Weizmann Institute of Science
1982 to 1984
MSc in Neurobiology The Hebrew University of Jerusalem
1976 to 1979
BSc

Skills:

Research in biochemistry, molecular biology and microbiology, drug development

Handy Biology Answer Book

view source

Author
Naomi Balaban

ISBN #
0780807782

The Handy Science Answer Book: Centennial Edition

view source

Author
Naomi E. Balaban

ISBN #
0780807278

Us Patents

Target Of Rnaiii Activating Protein (Trap)
view source
US Patent:

6689878, Feb 10, 2004
Filed:

Sep 12, 2001
Appl. No.:

09/953780
Inventors:

Naomi Balaban - Davis CA
Tzipora Goldkorn - Davis CA
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

C07H 2104
US Classification:

536 235, 435 691, 435325, 4353201
Abstract:

The present invention is directed to a protein isolated from that is the target of RAP, called TRAP, which is characterized by a molecular weight of about 21 KDa, is capable of being phosphorylated by RAP, and comprises an amino acid sequence of SEQ ID NO:2. In addition, the present invention is directed towards an antibody immunoreactive with TRAP that is preferably a monoclonal antibody or a humanized antibody but may be a polyclonal antibody. The invention provides a method of treating infection by administering such a TRAP-inhibiting agent. The invention also features methods for identifying compounds that inhibit TRAP activity and/or inhibit TRAP-RAP interaction.

Target Of Rnaiii Activating Protein(Trap)
view source
US Patent:

6747129, Jun 8, 2004
Filed:

Sep 10, 1999
Appl. No.:

09/393862
Inventors:

Naomi Balaban - Davis CA
Tzipora Goldkorn - Davis CA
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

C07K 1700
US Classification:

530350, 530820, 530825, 514 2, 435 733
Abstract:

The present invention is directed to a protein isolated from that is the target of RAP, called TRAP, which is characterized by a molecular weight of about 21 KDa, is capable of being phosphorylated by RAP, and comprises an amino acid sequence of SEQ ID NO:2. In addition, the present invention is directed towards an antibody immunoreactive with TRAP that is preferably a monoclonal antibody or a humanized antibody but may be a polyclonal antibody. The invention provides a method of treating infection by administering such a TRAP-inhibiting agent. The invention also features methods for identifying compounds that inhibit TRAP activity and/or inhibit TRAP-RAP interaction.

Methods And Compositions For The Treatment And Prevention Of Infections
view source
US Patent:

7067135, Jun 27, 2006
Filed:

Apr 19, 2001
Appl. No.:

09/839695
Inventors:

Naomi Balaban - Davis CA, US
International Classification:

A61K 39/02
A61K 39/00
A61K 39/40
A61K 39/38
A61B 5/055
US Classification:

4241901, 424 934, 424 9151, 424 9342, 4241651, 4241841, 4241851, 514 44, 5303882, 53038821, 536 237
Abstract:

The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, spp. , particularly.

Methods And Compositions For The Treatment And Prevention Of And Other Bacterial Infections
view source
US Patent:

7323179, Jan 29, 2008
Filed:

Feb 3, 2003
Appl. No.:

10/358448
Inventors:

Naomi Balaban - Davis CA, US
International Classification:

A61K 39/00
A61K 39/38
A61K 39/08
A61K 39/02
A61K 39/085
A61K 39/108
A61K 39/07
US Classification:

4242341, 4241841, 4241901, 4242361, 4242371, 4242411, 4242391, 4242461, 4242471, 4242571, 514 8, 514 2
Abstract:

The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes species.

Methods And Compositions For The Treatment And Prevention Of Infections
view source
US Patent:

7534857, May 19, 2009
Filed:

May 1, 2006
Appl. No.:

11/414350
Inventors:

Naomi Balaban - Hopkinton MA, US
Assignee:

Centegen, Inc. - Pikesville MD
International Classification:

C07K 2/00
C07K 4/00
C07K 5/00
C07K 7/00
C07K 14/00
C07K 16/00
C07K 17/00
A61K 38/00
A61K 38/04
A61K 39/00
A61K 39/38
A61K 39/02
A61K 39/085
A61K 39/09
US Classification:

530300, 530350, 530327, 530305, 530330, 4242341, 4242351, 4241851, 4241841, 4241901, 4242361, 4242371, 4242431
Abstract:

A biologically pure RNAIII inhibiting peptide (RIP), that includes five contiguous amino acids of the sequence YXPXTNF, where Xis C, W, I or a modified amino acid, and Xis K or S is provided. The RIP further includes amino acids having a sequence that differs from the sequence YXPXTNF by two substitutions or deletions, where Xis C, W, I or a modified amino acid, and Xis K or S. This agent offers improved protection against and treatment of infections, and related bacteria infections, in mammals.

Use Of Rip In Treating Infections
view source
US Patent:

7824691, Nov 2, 2010
Filed:

Apr 3, 2006
Appl. No.:

11/395293
Inventors:

Naomi Balaban - Hopkinton MA, US
Assignee:

Centegen, Inc. - Pikesville MD
International Classification:

A61K 38/00
A61K 38/16
A61K 39/38
A61K 39/00
A61K 39/02
A61K 39/085
A61K 39/09
A61K 39/08
A61K 39/108
A61K 39/07
A01N 37/18
A61F 13/00
A61F 2/00
A61F 6/06
US Classification:

4242341, 4241841, 4241901, 4242361, 4242371, 4242391, 4242411, 4242431, 4242461, 4242471, 4242571, 424422, 424423, 424430, 514 8, 514 2
Abstract:

The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition is advantageously used in a method of treatment of bacterial sepsis.

Methods And Compositions For The Treatment And Prevention Of And Other Bacterial Infections
view source
US Patent:

8067015, Nov 29, 2011
Filed:

May 26, 2006
Appl. No.:

11/441229
Inventors:

Naomi Balaban - Davis CA, US
International Classification:

A61K 39/00
A61K 39/38
A61K 39/09
A61K 39/02
A61K 39/085
US Classification:

4242431, 4241841, 4242361, 4242371
Abstract:

The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes species.

Methods And Compositions For The Treatment And Prevention Of Staphylococcus And Other Bacterial Infections
view source
US Patent:

20060252691, Nov 9, 2006
Filed:

May 25, 2006
Appl. No.:

11/440093
Inventors:

Naomi Balaban - Davis CA, US
International Classification:

A61K 38/16
A61K 38/10
A61K 38/08
US Classification:

514012000, 514016000, 514015000
Abstract:

The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes species.